Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
10/2004
10/20/2004EP1140941B1 Nitrogen containing heterobicycles as factor xa inhibitors
10/20/2004EP1002791B1 Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis
10/20/2004CN1171861C Halogenated amidino amino acid dervatives useful as nitric oxide synthase inhibitors
10/20/2004CN1171587C Gamma-contained aminobutyric acid derivatives solid compositions and preparation process thereof
10/20/2004CN1171586C Pharmaceutical compositions comprising monoamine oxidase B inhibitors
10/19/2004USRE38629 Bioavailability; non-insulin depedent diabetes; hypoglycemic agents; treating metabolic disorders, impaired glucose tolerance, and insulin resistance
10/19/2004CA2139929C Transdermal therapeutic system containing the active substance 17-.beta.-oestradiol (anhydrous)
10/18/2004CA2426115A1 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
10/14/2004WO2004087185A1 Process for preparing antibacterial and antioxidant fraction from seabuckthorn seeds (hippophae rhamnoides l.)
10/14/2004WO2004087168A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
10/14/2004WO2004087133A1 Crystalline n-formyl hydroxylamine compounds
10/14/2004WO2004087101A2 Oral formulations of cladribine
10/14/2004WO2004087100A2 Cladribine formulations for improved oral and transmucosal delivery
10/14/2004WO2004087076A2 Methods for inhibiting adipogenesis and for treating type 2 diabetes
10/14/2004WO2004087075A2 Compositions and methods for treating cancer
10/14/2004WO2004087074A2 Process for making substituted pyrazoles
10/14/2004WO2004087073A2 Treatment of demyelinating conditions
10/14/2004WO2004087072A2 Topical l-carnitine compositions
10/14/2004WO2004087071A2 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
10/14/2004WO2004087070A2 METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-FUNGAL AGENTS
10/14/2004WO2004087069A2 METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS
10/14/2004WO2004087068A2 Cxcr4 antagonists and methods of their use
10/14/2004WO2004087067A2 Treatment of aspergillus infections with thymosin alpha 1
10/14/2004WO2004087066A2 Hif-1 inhibitors
10/14/2004WO2004087064A2 Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase
10/14/2004WO2004087063A2 Use of erythropoietin in stroke recovery
10/14/2004WO2004087062A2 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
10/14/2004WO2004087061A2 Tubulin binding agents and corresponding prodrug constructs
10/14/2004WO2004087060A2 Filtered backprojection algorithms for compton cameras in nuclear medicine
10/14/2004WO2004087059A2 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
10/14/2004WO2004087058A2 Targeted mhc class i alpha3 vaccine delivery systems
10/14/2004WO2004087057A2 Methods for inhibition of angiogenesis
10/14/2004WO2004087055A2 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation
10/14/2004WO2004087054A2 Methods for modulating gastric secretion using prokineticin receptor antagonists.
10/14/2004WO2004087053A2 Dipeptidyl peptidase inhibitors
10/14/2004WO2004087052A2 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
10/14/2004WO2004087051A2 Ophthalmic compositions for treating ocular hypertension
10/14/2004WO2004087050A2 Mitotic kinesin inhibitors
10/14/2004WO2004087048A2 Benzamide modulators of metabotropic glutamate receptors
10/14/2004WO2004087047A2 Mutants of replication competent vaccinia virus
10/14/2004WO2004087046A2 TREATMENT OR PREVENTION OF cGMP-DEPENDENT PATHOPHYSIOLOGY WITH A MUTANT VARIANT OF SOLUBLE GUANYLYL CYCLASE
10/14/2004WO2004087045A2 Devices, methods, and compositions to prevent restenosis
10/14/2004WO2004087044A2 Drug target
10/14/2004WO2004087043A2 Stable ophthalmic formulation containing an antibiotic and a corticosteroid
10/14/2004WO2004078116A3 P38 inhibitors and methods of use thereof
10/14/2004WO2004075811A3 Subcutaneously-administered ganglioside-based vaccine compositions
10/14/2004WO2004073585A3 Methode of manufacturing glimepiride and the respective intermediate
10/14/2004WO2004073583A3 Use of antimuscarinic drugs for preventing the onset of epilepsy
10/14/2004WO2004071416A3 Novel inhibitors of formation of advanced glycation endproducts (ages)
10/14/2004WO2004071401A3 Hydroxamic acid derivatives as histone deacetylase inhibitors (hdca)
10/14/2004WO2004047623A3 Methods for identifying risk of breast cancer and treatments thereof
10/14/2004WO2004043367A3 Fused heterocyclic compounds and use thereof
10/14/2004WO2004032840A3 Compounds, compositions, and methods
10/14/2004WO2004032831A3 Metalization of microtubules
10/14/2004WO2004017916A3 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
10/14/2004WO2004006854A3 Method for identification of biologically active agents
10/14/2004US20040204586 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
10/14/2004US20040204498 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex
10/14/2004US20040204495 Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment of prevention of pain and/or headache disorders
10/14/2004US20040204462 E.g., l2-{3-[2-(4-Fluorophenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-6-methylbenzoic acid; lipid- and/or triglyceride-lowering properties; metabolic disorders; antidiabetic agents (type II); therapy of syndrome X; eating disorders; cardiomyopathy
10/14/2004US20040204448 For inhibiting PDE4(phosphodiesteases) in a mammal; of modulating the production of TNF- alpha; inhibiting matrix metalloproteinases, for therapy of undesired angiogenesis; therapy of cancer
10/14/2004US20040204432 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
10/14/2004US20040204359 Methods and compositions in treating pain and painful disorders using 16386,15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
10/14/2004US20040204346 Intermediate for preparing glycopeptide derivatives
10/14/2004US20040203140 comprises two culture compartments in fluid communication with each other and each culture compartment is transversed by a filter that prevents the exit of the cells
10/14/2004US20040203084 protein antigens for producing neutralizing antibodies; biodrugs
10/14/2004US20040202720 Delivery of immune response modifier compounds using metal-containing particulate support materials
10/14/2004US20040202717 Abuse-resistant oral dosage forms and method of use thereof
10/14/2004US20040202706 Methods of administering a dermatological agent to a subject
10/14/2004US20040202662 Humanised antibodies
10/14/2004US20040202626 siloxane free; thermoplastics; radiation transparent; lipsticks; mascara
10/14/2004US20040202623 POSS containing cosmetics and personal care products
10/14/2004US20040202622 extended polyhedral oligomeric silsesquioxanes (EPOSS); for skin and hair treatment
10/14/2004US20040202616 comprises magnesium stearate for improved storage stability; inhalers
10/14/2004CA2522441A1 Hif-1 inhibitors
10/14/2004CA2522147A1 Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase
10/14/2004CA2520828A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
10/14/2004CA2520682A1 Crystalline n-formyl hydroxylamine compounds
10/14/2004CA2520674A1 Process for making substituted pyrazoles
10/14/2004CA2520671A1 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
10/14/2004CA2520510A1 Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-fungal agents
10/14/2004CA2520460A1 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation
10/14/2004CA2520423A1 Treatment of demyelinating conditions
10/14/2004CA2520415A1 Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-proliferative agents
10/14/2004CA2520406A1 Cxcr4 antagonists and methods of their use
10/14/2004CA2520400A1 Treatment of aspergillus infections with thymosin alpha 1
10/14/2004CA2520392A1 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
10/14/2004CA2519998A1 Topical l-carnitine compositions
10/14/2004CA2519954A1 Benzamide modulators of metabotropic glutamate receptors
10/14/2004CA2519899A1 Ophthalmic compositions for treating ocular hypertension
10/14/2004CA2519803A1 Use of erythropoietin in stroke recovery
10/14/2004CA2518872A1 Devices, methods, and compositions to prevent restenosis
10/14/2004CA2518465A1 Dipeptidyl peptidase inhibitors
10/14/2004CA2516429A1 Stable ophthalmic formulation containing an antibiotic and a corticosteroid
10/13/2004EP1466888A1 Calcium receptor-active arylalkyl amines
10/13/2004EP1466594A2 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
10/13/2004EP1465894A2 Synthesis and purification of valacyclovir
10/13/2004EP1465864A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
10/13/2004EP1465656A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
10/13/2004EP1465618A2 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
1 ... 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 ... 295